R1	Has_value Arg1:T7 Arg2:T8	
R2	Has_value Arg1:T10 Arg2:T9	
R3	Has_value Arg1:T12 Arg2:T11	
R4	Has_value Arg1:T13 Arg2:T14	
R5	Has_value Arg1:T15 Arg2:T16	
R6	Has_qualifier Arg1:T15 Arg2:T17	
R7	Has_value Arg1:T18 Arg2:T19	
*	OR T23 T24
*	OR T20 T21 T22
R8	Has_qualifier Arg1:T20 Arg2:T23	
R9	Has_qualifier Arg1:T20 Arg2:T25	
R10	Has_index Arg1:T29 Arg2:T30	
R11	Has_index Arg1:T31 Arg2:T32	
*	OR T31 T29
R12	Has_temporal Arg1:T28 Arg2:T31	
R13	AND Arg1:T20 Arg2:T28	
R14	Has_qualifier Arg1:T34 Arg2:T36	
R15	AND Arg1:T20 Arg2:T34	
*	OR T40 T41 T42
R16	Subsumes Arg1:T39 Arg2:T40	
R17	Has_index Arg1:T46 Arg2:T47	
R18	Has_temporal Arg1:T45 Arg2:T46	
*	OR T45 T49
R19	Subsumes Arg1:T48 Arg2:T45	
*	OR T54 T55
R20	Has_multiplier Arg1:T54 Arg2:T56	
*	OR T60 T59
R21	Has_temporal Arg1:T58 Arg2:T60	
R22	AND Arg1:T54 Arg2:T58	
R23	Subsumes Arg1:T64 Arg2:T62	
*	OR T67 T66
R24	Has_temporal Arg1:T69 Arg2:T67	
R25	AND Arg1:T70 Arg2:T69	
R26	Subsumes Arg1:T65 Arg2:T64	
R27	Subsumes Arg1:T65 Arg2:T70	
R28	Has_value Arg1:T73 Arg2:T75	
R29	AND Arg1:T74 Arg2:T73	
R30	AND Arg1:T76 Arg2:T77	
R31	Has_index Arg1:T78 Arg2:T79	
R32	Has_temporal Arg1:T77 Arg2:T78	
R33	Has_value Arg1:T87 Arg2:T88	
R34	Has_value Arg1:T89 Arg2:T91	
R35	Has_value Arg1:T92 Arg2:T93	
R36	Has_value Arg1:T94 Arg2:T95	
R37	Has_value Arg1:T97 Arg2:T98	
R38	Has_value Arg1:T103 Arg2:T104	
R39	Has_index Arg1:T31 Arg2:T30	
T1	Parsing_Error 0 2	1.
T2	Parsing_Error 972 974	2.
T3	Parsing_Error 1032 1034	3.
T4	Parsing_Error 1166 1168	4.
T5	Parsing_Error 1503 1505	5.
T6	Parsing_Error 1542 1544	6.
T7	Measurement 1833 1843	Hemoglobin
T8	Value 1845 1853	≥ 9 g/dL
T9	Value 1873 1886	≥ 1.5 x 109/L
T10	Measurement 1855 1871	Neutrophil count
T11	Value 1904 1917	≥ 100,000/mm3
T12	Measurement 1888 1902	Platelet count
T13	Measurement 1919 1935	Serum creatinine
T14	Value 1937 1985	≤ 1.5x Institutional Upper Limit of Normal (ULN)
T15	Measurement 1990 2010	Creatinine Clearance
T16	Value 2011 2022	≥ 50 mL/min
T17	Qualifier 2027 2050	Cockcroft-Gault formula
T18	Measurement 2053 2068	Serum bilirubin
T19	Value 2070 2081	≤ 1.2 mg/dL
T20	Condition 104 132	primary peritoneal carcinoma
T21	Condition 123 132;85 99	carcinoma fallopian tube
T22	Condition 123 132;65 83	carcinoma epithelial ovarian
T23	Qualifier 22 31	recurrent
T24	Qualifier 35 45	persistent
T25	Qualifier 46 64	platinum-resistant
T28	Condition 138 157	measureable disease
T29	Temporal 186 197;208 240	after first line platinum-based chemotherapy
T30	Reference_point 192 197;208 240	first line platinum-based chemotherapy
T31	Temporal 186 191;201 240	after second line platinum-based chemotherapy
T32	Reference_point 201 240	second line platinum-based chemotherapy
T34	Procedure 252 270	treatment with PLD
T35	Drug 267 270	PLD
T36	Qualifier 274 283	indicated
T37	Undefined_semantics 274 283	indicated
T38	Subjective_judgement 274 283	indicated
T39	Procedure 285 307	Platinum-based therapy
T40	Drug 337 348	carboplatin
T41	Drug 350 359	cisplatin
T42	Drug 363 394	another organoplatinum compound
T43	Not_a_criteria 285 395	Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound.
T45	Measurement 438 466	platinum-free interval (PFI)
T46	Temporal 470 537	< 12 months after first- or second-line platinum-based chemotherapy
T47	Reference_point 488 537	first- or second-line platinum-based chemotherapy
T48	Condition 396 414	Platinum-resistant
T49	Condition 549 568	disease progression
T50	Procedure 585 624	second-line platinum-based chemotherapy
T53	Parsing_Error 627 704	Subjects are allowed to have received, but are not required to have received:
T54	Drug 721 738	cytotoxic regimen
T55	Drug 746 760	PARP inhibitor
T56	Multiplier 706 720	one additional
T58	Condition 803 810	disease
T59	Temporal 792 802	persistent
T60	Temporal 779 788	recurrent
T62	Drug 837 848	bevacizumab
T63	Undefined_semantics 803 810	disease
T64	Procedure 813 829	biologic therapy
T65	Procedure 867 892	primary treatment regimen
T66	Temporal 951 961	persistent
T67	Temporal 938 947	recurrent
T69	Condition 962 969	disease
T70	Procedure 910 919	treatment
T71	Context_Error 938 969	recurrent or persistent disease
T72	Undefined_semantics 938 969	recurrent or persistent disease
T73	Procedure 975 985	Histologic
T74	Condition 1007 1029	original primary tumor
T75	Value 986 999	documentation
T76	Procedure 1046 1058	radiographic
T77	Condition 1059 1078	disease progression
T78	Temporal 1079 1163	< 12 months after the last dose of first- or second-line platinum-based chemotherapy
T79	Reference_point 1097 1163	the last dose of first- or second-line platinum-based chemotherapy
T80	Condition 1199 1225	disease amenable to biopsy
T81	Subjective_judgement 1199 1225	disease amenable to biopsy
T82	Undefined_semantics 1199 1225	disease amenable to biopsy
T83	Non-query-able 1238 1295	willing to undergo pre- and post-treatment tumor biopsies
T84	Post-eligibility 1238 1295	willing to undergo pre- and post-treatment tumor biopsies
T85	Parsing_Error 1297 1318	Optional for Phase 1.
T86	Not_a_criteria 1320 1501	Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry.
T87	Measurement 1506 1529	ECOG performance status
T88	Value 1533 1539	0 or 1
T89	Measurement 1545 1586	Laboratory parameters for vital functions
T90	Undefined_semantics 1545 1586	Laboratory parameters for vital functions
T91	Value 1604 1616	normal range
T92	Measurement 2083 2090	AST/ALT
T93	Value 2092 2103	≤ 2.5 x ULN
T94	Measurement 2105 2125	Alkaline phosphatase
T95	Value 2127 2138	≤ 2.5 x ULN
T96	Parsing_Error 2140 2142	7.
T97	Person 2143 2146	Age
T98	Value 2147 2156	≥18 years
T99	Parsing_Error 2159 2161	8.
T100	Non-query-able 2162 2218	Able and willing to give valid written informed consent.
T101	Post-eligibility 2162 2218	Able and willing to give valid written informed consent.
T102	Parsing_Error 2220 2222	9.
T103	Measurement 2223 2234	Body weight
T104	Value 2235 2242	> 30 kg
